Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

The ‘KojoX’ method of cloning facilities around the globe keeps the CDMO agile in an industry fractured by geopolitical ...

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

The most notable strategic choice is prioritising myasthenia gravis (MG) and Sjögren's disease as lead indications while ...

WuXi AppTec highlighted the strength of its integrated CRDMO model and growing exposure to late-stage and commercial assets ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.